STOCK TITAN

WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
WuXi Biologics (2269.HK) has been awarded the EcoVadis Sustainability Rating's Platinum Medal, ranking in the top 1% of over 100,000 companies evaluated. The company has been recognized for outstanding performance across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, making it a trusted partner by global clients for its strong sustainability commitment.
Positive
  • None.
Negative
  • None.
  • Ranked in top 1% of the over 100,000 companies evaluated
  • Recognized for outstanding performance across all areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement
  • Seen as a trusted partner by global clients for its strong sustainability commitment

SHANGHAI, Dec. 8, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been awarded the EcoVadis Sustainability Rating's Platinum Medal, the highest level of recognition granted to the companies being evaluated.

EcoVadis is a leading ratings organization for the sustainability of supply chains. Businesses of all sizes rely on EcoVadis' expert intelligence and evidence-based ratings to improve the sustainability performance of their companies and their value chains. As a result of WuXi Biologics' outstanding performance across four core themes – Environment, Labor & Human Rights, Ethics, and Sustainable Procurement – it was ranked in the top 1% of the more than 100,000 companies evaluated worldwide.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very proud to receive the Platinum Medal from EcoVadis, which we see as a strong testament to our sustainable business strategy. The EcoVadis Sustainability Rating is an important reference for our partners worldwide – notably all the global pharmaceutical companies – in evaluating sustainability performance and the benefits of collaboration. We will continue to work with clients, suppliers, employees and other stakeholders to enhance our ESG capabilities and advance the common good of the global community."

The EcoVadis recognition follows other notable WuXi Biologics ESG achievements this year. In June, it signed the Science Based Targets initiative (SBTi) commitment letter, a new milestone towards the goal of net-zero. In September, the company became a signatory to the United Nations Global Compact, demonstrating its sustainability commitment. In November, it received an AAA rating from MSCI ESG Ratings.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts
ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-awarded-highest-platinum-medal-by-ecovadis-sustainability-rating-302009950.html

SOURCE WuXi Biologics

FAQ

What is the significance of WuXi Biologics receiving the EcoVadis Sustainability Rating's Platinum Medal?

WuXi Biologics receiving the EcoVadis Sustainability Rating's Platinum Medal signifies its outstanding performance across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, ranking it in the top 1% of over 100,000 companies evaluated.

What are some of the notable ESG achievements of WuXi Biologics this year?

Some of the notable ESG achievements of WuXi Biologics this year include signing the Science Based Targets initiative (SBTi) commitment letter, becoming a signatory to the United Nations Global Compact, and receiving an AAA rating from MSCI ESG Ratings.

What are the core themes across which WuXi Biologics has shown outstanding performance?

WuXi Biologics has shown outstanding performance across four core themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

Who is the CEO of WuXi Biologics?

Dr. Chris Chen is the CEO and Chairman of the ESG Committee at WuXi Biologics.

WUXI BIOLOGICS UNSP/ADR

OTC:WXXWY

WXXWY Rankings

WXXWY Latest News

WXXWY Stock Data

7.39B
3.62B
0.01%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
No 108 Meiliang Road Mashan

About WXXWY

wuxi biologics provides an open-access, integrated technology platform for biologics drug development. we are the only true service platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. our single-source approach to biologics development saves our clients critical time and money. see below how our experience, capacities and quality make us a world leading (cdmo). experience wuxi biologics’ leadership team consists of industry experts with 15-20 years of experience in biological drug development in the u.s./eu. while at wuxi this team has contributed to 1 bla and 66 worldwide inds in just 3 years! expertise wuxi biologics has over 170+ returnees from large pharma and small biotechs in the u.s./eu. these scientists cover all facets of drug development from discovery to manufacture of final drug product. capacity and capabilities we have strong technical capabilities and an open-access